Illumina, Inc. (NASDAQ:ILMN) EVP Omead Ostadan sold 1,671 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $195.26, for a total transaction of $326,279.46. Following the completion of the transaction, the executive vice president now owns 24,571 shares in the company, valued at $4,797,733.46. The sale was disclosed in a filing with the SEC, which is available through this link.

Omead Ostadan also recently made the following trade(s):

  • On Friday, July 7th, Omead Ostadan sold 1,672 shares of Illumina stock. The stock was sold at an average price of $172.73, for a total transaction of $288,804.56.

Illumina, Inc. (ILMN) traded up 0.82% on Wednesday, hitting $199.23. 1,021,449 shares of the company’s stock were exchanged. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.82. The company has a market cap of $29.09 billion, a PE ratio of 39.97 and a beta of 0.83. The company’s 50-day moving average price is $176.74 and its 200-day moving average price is $172.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same quarter in the prior year, the firm earned $0.86 EPS. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/illumina-inc-ilmn-evp-omead-ostadan-sells-1671-shares.html.

A number of hedge funds have recently added to or reduced their stakes in ILMN. Advocacy Wealth Management Services LLC acquired a new stake in Illumina during the first quarter valued at approximately $102,000. Gemmer Asset Management LLC increased its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC acquired a new stake in Illumina during the first quarter valued at approximately $117,000. Penserra Capital Management LLC increased its stake in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares during the period. Finally, Paradigm Asset Management Co. LLC increased its stake in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 93.81% of the company’s stock.

A number of equities analysts have commented on the stock. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price on the stock in a research note on Monday, April 24th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co restated an “overweight” rating and issued a $250.00 target price on shares of Illumina in a research note on Wednesday, August 2nd. BidaskClub downgraded shares of Illumina from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $175.00 target price (up from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $177.01.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.